NRX Pharmaceuticals earnings date
NRX Pharmaceuticals (B1Q) Q2 2026 Earnings Report
DE:B1Q Q2 2026 EPS Results
- Actual EPS
- -EUR 0.40
- Consensus EPS
- -EUR 0.10
- Beat/Miss
- Missed by -EUR 0.30
- One Year Ago EPS
- -EUR 0.89
DE:B1Q Q2 2026 Revenue Results
- Actual Revenue
- EUR 998.88K
- Expected Revenue
- EUR 1.21M
- Beat/Miss
- Missed by -EUR 207.76K
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/17/2026
- Time
- Before Open
- Conference Call
- Monday, August 17, 2026
NRX Pharmaceuticals's next earnings date is estimated for November 17, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
The call conveyed significant strategic and technical progress across multiple fronts: near-term commercialization steps (ANDA and launch-stock orders), a strengthened balance sheet (cash up ~242%), a materially expanded development pipeline via the GeNeuro acquisition, and a high-impact DARPA/military partnership with a 400-patient SPARC-TMS trial. These positives are tempered by ongoing net operating losses (operating loss up ~48.7%), regulatory/contracting uncertainties, dependence on nondilutive government funding, and the need for further financing or successful commercial milestones beyond the ~1-year cash runway. Overall, the tone is cautiously optimistic: strong strategic wins and funding momentum outweigh current financial and execution risks, but key approvals, contracts and trial execution remain critical near-term milestones.
Management guided that the preservative‑free ketamine ANDA is targeted for 2026 approval after completing the first review cycle with a single remaining major deficiency (FDA requested manufacturer attestation that the vial Luer‑lock is used in products shipping >12 million units/year), 5 million units of launch stock have been ordered and the ketamine market is estimated at ~$750M; the NRX‑100 NDA is being advanced with a 2027 approval goal (PDUFA fee ~ $5M) supported by real‑world evidence from ~65,000 Americans; the DARPA‑backed SPARC‑TMS Phase II/III trial (NRx as prime contractor) is planned to enroll ~400 patients (240 at HOPE/Harvard‑McLean and 160 at military treatment facilities) and could expand NRX‑101’s addressable market to >15 million treatment‑resistant depression patients; GeNeuro’s GNK‑301 first‑in‑human is targeted for July 2027 with initial congressional/DoD funding efforts (first $3M CDMRP submission and ~$80M added to the 2027 Defense appropriation) under way; and financially NRx reported $26.7M cash as of June 30, 2026 (vs $7.8M at Dec 31, 2025), raised >$22M gross in its recent public offering, posted a 6‑month net loss of $18M (vs $23.1M prior year) and a net operating loss of $11.3M (vs $7.6M), and believes current resources plus its ATM facility will support operations for at least one year.
- ANDA for Preservative-Free Ketamine Nearing ApprovalSingle major deficiency (Luer lock attestation) addressed and attestation submitted to FDA; company aiming for 2026 approval and has ordered 5 million units of launch stock.
- Progress Toward NRX-100 NDAAdvancing NDA for NRX-100 to treat depression with guidance from a presidential executive order and congressional budget language supporting use of real-world evidence; company targeting 2027 approval.
- DARPA-Funded SPARC-TMS Trial and Military PartnershipSelected as prime contractor for an FDA-approved Phase II/III SPARC-TMS trial combining NRX-101 with robotic TMS; trial expected to enroll ~400 patients (240 in HOPE/Harvard sites + 160 in military treatment facilities) with funding routed through the military (contracting ongoing).
- Material Expansion of NRX-101 Market OpportunityNRX-101 being evaluated beyond suicidal bipolar depression for treatment-resistant depression with an addressable U.S. market of >15 million patients; potential to restore deployability/readiness for military and first responders.
- Acquisition of GeNeuro PortfolioAcquisition finalized in June (Swiss courts) adding two clinical-stage monoclonal antibodies: GNK-301 (targeting HERV-K for ALS) and temelimab (MS, type 1 diabetes, potential schizophrenia application), creating a transformative longer-term pipeline.
- Forward-Funded ALS Program and Near-Term MilestonesGNK-301 selected in first round of congressionally-directed medical research program for drug development/biomarker funding; first-in-human GNK-301 trial targeted for July 2027; additional defense appropriations and CDMRP opportunities identified (applied for initial $3M).
- Stronger Cash Position and Capital RaiseCash and cash equivalents of $26.7M as of June 30, 2026 versus $7.8M at 12/31/2025 — an increase of ~242.3% — primarily from a public offering with gross proceeds >$22M; management expects current resources plus ATMs to support operations for at least one year.
- HOPE Therapeutics Clinic Footprint ExpansionExpanded HOPE Therapeutics network to 5 clinical locations in Florida, providing a platform to deploy neuronavigation, robotic TMS and neuroplastic-assisted care and to support clinical trials (e.g., SPARC-TMS).
DE:B1Q Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Nov 17, 2026 | 2026 (Q3) | -0.19- | -0.24 | ― | ― |
| Aug 17, 2026 | 2026 (Q2) | -0.10-0.40 | -0.89 | 55.10% (+0.49) | |
| May 18, 2026 | 2026 (Q1) | 0.19-0.04 | -0.31 | 88.24% (+0.27) | |
| Mar 24, 2026 | 2025 (Q4) | 0.010.01 | -0.66 | 101.38% (+0.67) | |
| Nov 17, 2025 | 2025 (Q3) | -0.02-0.24 | -0.14 | -80.00% (-0.11) | |
| Aug 18, 2025 | 2025 (Q2) | -0.14-0.89 | -0.68 | -30.67% (-0.21) | |
| May 15, 2025 | 2025 (Q1) | -0.26-0.31 | -0.67 | 54.05% (+0.36) | |
| Mar 17, 2025 | 2024 (Q4) | -0.33-0.66 | -0.45 | -44.80% (-0.20) | |
| Nov 14, 2024 | 2024 (Q3) | -0.50-0.14 | -0.64 | 78.57% (+0.50) | |
| Aug 13, 2024 | 2024 (Q2) | -0.63-0.68 | -1.09 | 37.50% (+0.41) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

